By: Todd Liao, Morgan Lewis
The proposed rules prohibit outbound transfers of biotechnology platform ownership but expressly exempt ownership-retaining product licenses. Multinational corporations should structure transactions as product-specific licenses rather than platform or entity acquisitions to preserve deal viability.